Brief: Lisata Therapeutics Announces Completion Of Enrollment In Phase 2B Ascend Trial Of Lsta1
12/12/2023 13:33
Dec 12 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
PHASE
2B ASCEND TRIAL OF LSTA1 IN METASTATIC PANCREATIC DUCTAL
ADENOCARCINOMA
* LISATA THERAPEUTICS INC - TOP-LINE PLACEBO-CONTROLLED,
BLINDED,
RANDOMIZED DATA NOW EXPECTED IN Q4 OF 2024
* LISATA THERAPEUTICS INC - EXPECTS COMPLETE DATA SET OF
ALL 155
PATIENTS FROM STUDY BY MID-2025.
Source text for Eikon: ID:nGNX4wsMDF
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Lisata Therapeutics Announces New Method Of Use Patent Granted For Certepetide In The Treatment Of Pancreatic Cancer And Other Solid Tumors
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
U.S. STOCKS ON THE MOVE -Expeditors International, Waters, Ameresco